Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Nkarta, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Adicet Therapeutics
National Cancer Institute (NCI)
Hoffmann-La Roche
Actuate Therapeutics Inc.
Pfizer
Acerta Pharma BV
iOnctura
Swiss Cancer Institute
National Cancer Institute (NCI)